Site-specific modification of positively-charged surfaces on human serum albumin by malondialdehyde

Biochemical and Biophysical Research Communications

Volumn 371, Issue 1, 2008, Pages 28-32

  Ishii, Takeshi ^a   Ito, Sohei ^a   Kumazawa, Shigenori ^a   Sakurai, Toyo ^b   Yamaguchi, Satoru ^b   Mori, Taiki ^a   Nakayama, Tsutomu ^a   Uchida, Koji ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Electrostatic potential; Human serum albumin; Malondialdehyde; Mass spectrometry; Protein modification

Indexed keywords

ACROLEIN; ALDEHYDE; HUMAN SERUM ALBUMIN; LYSINE; MALONALDEHYDE; PROTEINASE;

ARTICLE; ELECTRIC POTENTIAL; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN STRUCTURE; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, LIQUID; ELECTROSTATICS; HUMANS; LYSINE; MALONDIALDEHYDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTEIN CONFORMATION; SERUM ALBUMIN; TANDEM MASS SPECTROMETRY;

EID: 46349087190     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.03.140     Document Type: Article

References (34)

1. Haberland M.E., Fogelman A.M., and Edwards P.A. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc. Natl. Acad. Sci. USA 79 (1982) 1712-1716
2. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 28 (2000) 1685-1696
3. Stone K., Uzieblo A., and Marnett L.J. Studies of the reaction of malondialdehyde with cytosine nucleosides. Chem. Res. Toxicol. 3 (1990) 467-472
4. ε-(2-propenol) lysine in proteins. Arch. Biochem. Biophys. 346 (1997) 45-52
5. ε-(2-propenal)lysine as a urinary metabolite of malondialdehyde. J. Biol. Chem. 260 (1985) 15427-15431
6. Kikugawa K., and Ido Y. Studies on peroxidized lipids. V. Formation and characterization of 1,4-dihydropyridine-3,5-dicarbaldehydes as model of fluorescent components in lipofuscin. Rapid Commun. Lipids 19 (1984) 600-608
7. Uchida K. Lipofuscin-like fluorophores originated from malondialdehyde. Free Radic. Res. 40 (2006) 1335-1338
8. Schmitt A., Gasic-Milenkovic J., and Schmitt J. Characterization of advanced glycation end products: mass changes in correlation to side chain modifications. Anal. Biochem. 346 (2005) 101-106
9. Aldini G., Orioli M., and Carini M. α,β-Unsaturated aldehydes adducts to actin and albumin as potential biomarkers of carbonylation damage. Redox Rep. 12 (2007) 20-25
10. Del Rio D., Stewart A.J., and Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 15 (2005) 316-328
11. Vay D., Parodi M., Rolla R., Mottaran E., Vidali M., Bellomo G., and Albano E. Circulating antibodies recognizing malondialdehyde-modified proteins in healthy subjects. Free Radic. Biol. Med. 30 (2001) 277-286
12. Mottaran E., Stewart S.F., Rolla R., Vay D., Cipriani V., Moretti M., Vidali M., Sartori M., Rigamonti C., Day C.P., and Albano E. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic. Biol. Med. 32 (2002) 38-45
13. Palacio J.R., Iborra A., Ulcova-Gallova Z., Badia R., and Martínez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin. Exp. Immunol. 144 (2006) 217-222
14. Slatter D.A., Avery N.C., and Bailey A.J. Identification of a new cross-link and unique histidine adduct from bovine serum albumin incubated with malondialdehyde. J. Biol. Chem. 279 (2004) 61-69
15. Marnett L.J., and Tuttle M.A. Comparison of the mutagenicities of malondialdehyde and the side products formed during its chemical synthesis. Cancer Res. 40 (1980) 276-282
16. Wardell M., Wang Z., Ho J.X., Robert J., Ruker F., Ruble J., and Carter D.C. The atomic structure of human methemalbumin at 1.9 Å. Biochem. Biophys. Res. Commun. 291 (2002) 813-819
17. Kinoshita K., and Nakamura H. eF-site and PDBjViewer: database and viewer for protein functional sites. Bioinformatics 20 (2004) 1329-1330
18. McRee D.E. Differential evolution for protein crystallographic optimizations. Acta. Crystallogr. D Biol. Crystallogr. 60 (2004) 2276-2279
19. Ishii T., Kumazawa S., Sakurai T., Nakayama T., and Uchida K. Mass spectroscopic characterization of protein modification by malondialdehyde. Chem. Res. Toxicol. 19 (2006) 122-129
20. Slatter D.A., Murray M., and Bailiey A.J. Formation of a dihydropyridine derivative as a potential cross-link derived from malondialdehyde in physiological systems. FEBS Lett. 421 (1998) 180-184
21. Yamada S., Kumazawa S., Ishii T., Nakayama T., Itakura K., Shibata N., Kobayashi M., Sakai K., Osawa T., and Uchida K. Immunochemical detection of a lipofuscin-like fluorophore derived from malondialdehyde and lysine. J. Lipid Res. 42 (2001) 1187-1196
22. Baynes J.W., and Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28 (2000) 1708-1716
23. Nagai R., Matsumoto K., Ling X., Suzuki H., Araki T., and Horiuchi S. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 49 (2000) 1714-1723
24. Shokat K.M., Leumann C.J., Sugasawara R., and Schultz P.G. A new strategy for the generation of catalytic antibodies. Nature 338 (1989) 269-271
25. Honig B., and Nicholls A. Classical electrostatics in biology and chemistry. Science 268 (1995) 1144-1149
26. Kinoshita K., Furui J., and Nakamura H. Identification of protein functions from a molecular surface database, eF-site. J. Struct. Funct. Genomics 2 (2001) 9-22
27. He X.M., and Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 358 (1992) 209 J. Struct. Funct. Genomics 215.
28. Warshel A. Electrostatic origin of the catalytic power of enzymes and the role of preorganized active sites. J. Biol. Chem. 273 (1998) 27035-27038
29. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., and Curry S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 353 (2005) 38-52
30. Bhattacharyya R., Pal D., and Chakrabarti P. Disulfide bonds, their stereospecific environment and conservation in protein structures. Protein Eng. Des. Sel. 17 (2004) 795-808
31. Sudlow G., Birkett D.J., and Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11 (1975) 824-832
32. Ishii T., Tatsuda E., Kumazawa S., Nakayama T., and Uchida K. Molecular basis of enzyme inactivation by an endogenous electrophile 4-hydroxy-2-nonenal: identification of modification sites in glyceraldehyde-3-phosphate dehydrogenase. Biochemistry 42 (2003) 3474-3480
33. Ahmed N., Dobler D., Dean M., and Thornalley P.J. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J. Biol. Chem. 280 (2005) 5724-5732
34. Szapacs M.E., Riggins J.N., Zimmerman L.J., and Liebler D.C. Covalent adduction of human serum albumin by 4-hydroxy-2-nonenal: kinetic analysis of competing alkylation reactions. Biochemistry 45 (2006) 10521-10528